MLP Care 1Q24 Meeting Notes

We attended MLP Care's analyst meeting to evaluate the company's 1Q24 financial results, current operations, and outlook. The growing hospital portfolio and the increase in insurance premiums enabled MPARK to have a strong operational quarter. We maintain our buy recommendation for MPARK with a target price of 385 TL and continue to keep it in our Model Portfolio.